Loading stock data…
CELU
$0.96+0.02 (+2.43%)
Market ClosedLast close May 1
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celularity Inc. in the Healthcare sector is trading at $0.96. The stock is currently near its 52-week low of $0.93, remaining 48.8% below its 200-day moving average. Technical signals show oversold RSI of 20 and bearish MACD signal, explaining why CELU maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 20) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.96
Potential Upside
5%
Whystock Fair Value$1.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$34.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.08%
Volume
Today's trading volume
698,995
Recent News
NEXGEL, Inc. Q4 2025 Earnings Call Summary
Moby summary of NEXGEL, Inc.'s Q4 2025 earnings call
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is...
Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024)
Celularity ( NASDAQ:CELU ) Second Quarter 2025 Results Key Financial Results Revenue: US$5.74m (down 53% from 2Q 2024...
Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last week
NasdaqCM:CELU 1 Year Share Price vs Fair Value Explore Celularity's Fair Values from the Community and select yours Key...